Zevra Therapeutics (ZVRA) Other Non-Current Assets (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Other Non-Current Assets of $143000.0 for Q1 2026, little changed on a QoQ basis from $143000.0 in Q4 2025, and down 51.19% year-over-year from $293000.0 in Q1 2025.
Zevra Therapeutics (ZVRA) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $143000.0 for Q1 2026.
- Quarterly Other Non-Current Assets fell 51.19% year-over-year to $143000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $143000.0 (down 51.19% YoY) and the FY2025 annual result came in at $143000.0, down 62.76% from the prior year.
- Other Non-Current Assets was $143000.0 for Q1 2026 at Zevra Therapeutics, roughly flat from $143000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.8 million in Q1 2024 and bottomed at $53000.0 in Q4 2022.
- A 5-year average of $356466.7 and a median of $153000.0 in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 87.9% — and 2024, when it jumped 3269.81%.
- Zevra Therapeutics' Other Non-Current Assets stood at $53000.0 in 2022, then surged by 77.36% to $94000.0 in 2023, then surged by 308.51% to $384000.0 in 2024, then tumbled by 62.76% to $143000.0 in 2025, then changed by 0.0% to $143000.0 in 2026.
- Business Quant data shows ZVRA's Other Non-Current Assets at $143000.0 in Q1 2026, $143000.0 in Q4 2025, and $153000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 143,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143,000.00 |
| Dec 31, 2025 | 143,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 220,000.00 |
| Mar 31, 2025 | 293,000.00 |
| Dec 31, 2024 | 384,000.00 |
| Sep 30, 2024 | 512,000.00 |
| Jun 30, 2024 | 875,000.00 |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 94,000.00 |
| Sep 30, 2023 | 148,000.00 |
| Jun 30, 2023 | 53,000.00 |
| Mar 31, 2023 | 53,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Mar 31, 2022 | 437,000.00 |
| Dec 31, 2021 | 438,000.00 |
| Sep 30, 2021 | 439,000.00 |
| Jun 30, 2021 | 437,000.00 |
| Mar 31, 2021 | 437,000.00 |
| Dec 31, 2020 | 438,000.00 |